Generic Name and Formulations:
Patiromer 8.4g, 16.8g, 25.2g; per pkt; pwd for oral susp.
Indications for VELTASSA:
Limitations Of use:
Not for emergency treatment for life-threatening hyperkalemia due to its delayed onset of action.
Give at least 3hrs before or 3hrs after other oral medications. Take with food. Initially 8.4g once daily. Adjust dose in 8.4g increments as needed at ≥1-week intervals to obtain desired serum potassium target range; max 25.2g/day.
Monitor serum potassium, magnesium. Consider magnesium supplementation if low serum levels develop. Severe constipation, bowel obstruction or impaction, abnormal post-op bowel motility disorders; avoid.
May reduce absorption and efficacy of other oral medications; separate dosing by at least 3hrs.
Constipation, hypomagnesemia, diarrhea, nausea, abdominal discomfort, flatulence.
Single-use packets (8.4g)—4, 30; (16.8g, 25.2g)—30
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Risk for Cardiovascular Disease Higher in Survivors of Testicular Cancer
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|